Internet-delivered Parent-Child Interaction for Parents of Children 2-7 Years With Disruptive Behaviors
Launched by KAROLINSKA INSTITUTET · Feb 10, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new online program called Internet-delivered Parent-Child Interaction Therapy (iPCIT) for parents of children aged 2 to 7 years who show disruptive behaviors, like tantrums or aggression. The study aims to see if this brief online therapy can help reduce these challenging behaviors and improve how parents and children interact with each other. Parents will participate in a 10-week program, completing weekly questionnaires to share their experiences and progress.
To be eligible for this study, children must be between 2 and 7 years old and show significant disruptive behaviors. They should also have at least a basic ability to understand and communicate, similar to an average 2-year-old. However, children with severe autism or parents who struggle with the Swedish language may not qualify. This is a great opportunity for families looking for support in managing their child's behavior in a convenient online format.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 2-7 years
- • Disruptive behaviors as assessed with Eyberg Child Behavior Inventory (ECBI) ≥126 for boys and ≥121 for girls (which corresponds to the 90th percentile according to Swedish norms)
- • Language ability equivalent to at least an average 2-year-old, defined as a vocabulary of ≥ 25 word and ability to understand simple instructions, assessed with a language screening form
- Exclusion Criteria:
- • Severe autism spectrum condition (autism level 2 or 3 or equivalent functioning)
- • parents who are not proficient enough in the Swedish language to complete questionnaries and receive therapy without an interpreter
- • Presence of severe parental psychiatric disorders such as psychosis or suicidal ideations
- • Ongoing severe psychosocial distress such as custody dispute.
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Marianne Bonnert, PhD
Principal Investigator
Centre for Psychiatry Research, Karolinska Institutet & Stockholm Health Care Stockholm Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported